Integral Dental has announced the launch of its first product, OraclePI, the only early diagnostic test for peri-implant disease. This test provides a disease diagnosis and personalized care plan recommendations based on patient-specific data. Dental implants are an important option for patients with missing teeth, but while implant success rates are high, the greatest risk of failure is an infection of the surrounding tissue, known as peri-implantitis. Integral’s OraclePI product enables clinicians to gain insight into 100% of the bacteria present at the implant site, assess the state of infection, and receive recommendations on the most effective antibiotics and other treatments.
“This has the potential to improve patient outcomes and drive profitability for dental practices,” said Rachel Raymond, CEO of Integral Dental. “As the demand for implants grows, we’re excited to offer an option for personalized management.”
By combining cutting-edge genomic sequencing and AI, OraclePI empowers dentists with actionable insights to improve patient outcomes through personalized care.
“We’ve worked hard to ensure our processes fit seamlessly into the daily workflow of the dental office,” said Matt Getz, COO of Integral Dental. “Our $110-per-test cost for dentists is part of the innovation we’re bringing to the table.”
Early interventions in peri-implant disease are often more effective and less invasive than treatments at advanced stages of infection. Performing a diagnostic test as part of routine implant management can help clinicians identify problems early and keep patients healthy.
“The specific antibiotic recommendations allow us to practice true personalized medicine,” said Dr. Peter Joseph, DMD, clinical advisor to Integral Dental. “I plan to integrate this tool into my practice and encourage all my referring doctors to do the same. The better the information, the better we can help patients.”
Diagnosing peri-implant disease is just the beginning for Integral’s technology platform. Integral’s vision extends beyond oral health to address systemic diseases triggered by oral pathogens, such as cardiovascular disease, pre-term birth, rheumatoid arthritis, and colon cancer.
By diagnosing and treating oral pathogens early and effectively, healthcare costs can be significantly reduced, and patient outcomes can be improved. Integral Dental continues to explore innovative applications for OraclePI, bridging the gap between oral health and broader medical care.
OraclePI is now available for purchase and is being offered in 10-kit packs for a limited time. To learn more and add Integral to the services you offer patients, visit IntegralDental.bio.
About Integral
Integral is a biotechnology company dedicated to closing the gap between oral and systemic health. Its innovation is based on Next-Generation Sequencing and Machine Learning technology and is driven by co-founders Rachel Raymond and Matt Getz. The founders bring extensive biotech and healthcare executive experience, MBAs from Harvard Business School, and a passion for preventative medicine to this large, global health challenge.
Integral is a resident company of Johnson & Johnson Innovation—JLABS, a premier life sciences incubator program in Washington, DC.
